Arbaclofen
As of the edition of 20 October 2026, Arbaclofen is a small molecule: stopped in 2019; acts on GABBR1 and GABBR2.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2019
- Kind
- Small molecule
- Registered trials
- 16, 5 stopped early
- Disease areas
- Mental health; Nervous system; Immune system; Bones, joints and muscles; Inherited and neonatal
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 3 | 3 | 0 | 0 |
| Phase 1 | 2 | 1 | 0 | 1 |
| Phase 2 | 4 | 2 | 0 | 1 |
| Phase 3 | 7 | 3 | 1 | 3 |
| All trials | 16 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Seaside Therapeutics | Lead sponsor of trials | 2009 to now |
| RVL Pharmaceuticals | Lead sponsor of trials | 2012 to now |